banner

The official advocacy organization for pharmacist women in the United States

45,000+ Members

45,000+ Members

Over 6 Million posts, comments and reactions in 2020

Over 6 Million posts, comments and reactions in 2020

60,000+ Followers on social media platforms

60,000+ Followers on social media platforms

The Largest Community of Women Pharmacists in the US

pharmacist moms

Founded in 2017, Pharmacists Moms Group was created to provide women pharmacists the opportunity to network, collaborate and offer genuine feedback in a closed-door, trusted setting. The organization has quickly grown to over 45,000 members and 60,000 followers on our social media platforms.

Pharmacy News
View More
Study Confirms Benefit of Rivaroxaban for Secondary Prevention of Venous Thromboembolism in Patients With Cancer

At 3 and 6 months, rivaroxaban was found to be as effective and safe as apixaban in the composite outcome of recurrent venous thromboembolism or bleeding-related hospitalization.

Final Analysis of MONARCH 2 Trial Results Confirms Overall Survival Endpoint

The phase 3 clinical trial shows that the 5-year OS for patients with HR+/HER2- advanced breast cancer in the abemaciclib plus fulvestrant group was 41.2% vs 29.2% for the placebo arm.

Preclinical Data Suggests Combination Abilities of OP-1250, Palbociclib for Breast Cancer at SABCS

OP-1250 and palbociclib showed “enhanced suppression of tumor growth” in preclinical mouse model studies, according to expert who presented his findings in a poster at the San Antonio Breast Cancer Symposium 2022.

TDM1, Radiation Considered Safe for Patients with Early-Stage HER2-Positive Breast Cancer

Expert sits with Pharmacy Times to share the promising results of a study that evaluated the safety of a new antibody drug conjugate with radiation therapy.

Capivasertib Plus Fulvestrant Improves PFS in Those With Advanced HR+/HER2- Breast Cancer

Results from the phase 3 CAPItello-291 clinical trial show that the combination doubled the median progression-free survival compared with the placebo in patients with HR-positive, HER2-negative advanced breast cancer.

Updated USPSTF Guidelines Show Benefits of Screening for Obstructive Sleep Apnea Do Not Outweigh Harms

The decision is updated from a 2017 recommendation to screen people for obstructive sleep apnea, which can lead to daytime sleepiness and other adverse outcomes.

Official Media Partner

Official Media Partner

Official CE Partner

Official CE Partner

Founder of Women Pharmacist Day

Founder of Women Pharmacist Day
pharmacist moms group logo
Stay In Touch
an mjh life sciences brand

© 2021 MJH Life Sciences and Pharmacy Times®. All rights reserved.

Privacy Policy